Phase 2/3 clinical trial of troriluzole fails to demonstrate efficacy in Alzheimer's disease (AD)

Preliminary analysis found troriluzole, a glutamate modulator, is not efficacious as a symptomatic treatment of patients with mild and moderate AD. Additional biomarker data/secondary analyses awaited to determine if it may provide benefit in early AD as disease modifying agent.

Source:

Biospace Inc.